title: New insights and modern treatment of AL amyloidosis.
abstract: Systemic amyloidosis is a rare disease that is rarely cured. Systemic immunoglobulin light-chain amyloidosis (AL) is the most common type, usually the result of monoclonal light chains produced by a relatively indolent small plasma cell clone in the bone marrow. In AL, the direct toxicity of light chains, their misfolded intermediates, and deposition as amyloid fibrils in vital organs cause organ dysfunction and death. Often the diagnosis is delayed and the disease is advanced at presentation. Early diagnosis is possible with vigilance in clinical situations such as for patients with monoclonal gammopathy of undetermined significance who develop albuminuria or elevated cardiac biomarkers. Treatment is aimed at eradicating the clonal disease and restoring organ function; options include high dose melphalan followed by autologous stem cell transplantation, oral melphalan and dexamethasone, bortezomib-based combination chemotherapy and immunomodulatory agents such as lenalidomide or pomalidomide combined with dexamethasone. Cardiac involvement at baseline and the free light-chain hematologic response to therapy determine overall survival. Following measures of organ disease with cardiac and other biomarkers and of hematologic disease with serum free light chains is necessary to gauge organ and hematologic responses to therapy.
authors.affiliation: Tufts Medical Center and Tufts University School of Medicine, 800 Washington Street, Boston, MA, 02111, USA, cchaulagain@tuftsmedicalcenter.org.
authors.forename: Chakra P
authors.initials: CP
authors.lastname: Chaulagain
authors.forename: Raymond L
authors.initials: RL
authors.lastname: Comenzo
mesh_terms: D000686:Amyloidosis / Q000175:diagnosis / Q000628:therapy*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000502:physiology; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D019653:Myeloablative Agonists / Q000627:therapeutic use; D012307:Risk Factors; D033581:Stem Cell Transplantation; D014182:Transplantation, Autologous
chemical_list: D000970:Antineoplastic Agents; D007147:Immunoglobulin Light Chains; D007166:Immunosuppressive Agents; D019653:Myeloablative Agonists
references.citation: Clin Chem. 2009 Aug;55(8):1517-22
references.pmid: 19520758
references.citation: Mayo Clin Proc. 1989 Dec;64(12):1505-19
references.pmid: 2513459
references.citation: Am J Med. 1996 Mar;100(3):290-8
references.pmid: 8629674
references.citation: Br J Haematol. 2003 Jul;122(1):78-84
references.pmid: 12823348
references.citation: Oncology (Williston Park). 2011 Jun;25(7):626, 628-9, 632-3
references.pmid: 21888262
references.citation: Blood. 2009 Oct 8;114(15):3147-57
references.pmid: 19617578
references.citation: Blood. 2002 Jun 15;99(12):4276-82
references.pmid: 12036853
references.citation: Blood. 1992 Apr 1;79(7):1817-22
references.pmid: 1558973
references.citation: Neurology. 2012 Aug 21;79(8):785-92
references.pmid: 22843282
references.citation: Amyloid. 2011 Jun;18 Suppl 1:135-6
references.pmid: 21838462
references.citation: Zhonghua Xue Ye Xue Za Zhi. 2013 Apr;34(4):345-8
references.pmid: 23668210
references.citation: J Intern Med. 2004 Feb;255(2):159-78
references.pmid: 14746554
references.citation: Leukemia. 2013 Apr;27(4):823-8
references.pmid: 23014566
references.citation: Subcell Biochem. 2012;65:609-42
references.pmid: 23225018
references.citation: Br J Haematol. 2007 Oct;139(2):224-33
references.pmid: 17897298
references.citation: Blood. 2012 May 10;119(19):4387-90
references.pmid: 22331187
references.citation: J Clin Oncol. 2004 Sep 15;22(18):3751-7
references.pmid: 15365071
references.citation: Clin Lymphoma Myeloma Leuk. 2012 Feb;12(1):49-58
references.pmid: 22100494
references.citation: Blood. 2004 Apr 15;103(8):2936-8
references.pmid: 15070667
references.citation: Blood. 2009 Dec 3;114(24):4957-9
references.pmid: 19797517
references.citation: Blood. 2010 Jul 29;116(4):522-8
references.pmid: 20375312
references.citation: Semin Hematol. 1995 Jan;32(1):45-59
references.pmid: 7878478
references.citation: Leukemia. 2012 Nov;26(11):2317-25
references.pmid: 22475872
references.citation: Am J Pathol. 2005 Jan;166(1):197-208
references.pmid: 15632012
references.citation: Blood Rev. 2012 Jul;26(4):137-54
references.pmid: 22537397
references.citation: Blood. 2012 May 10;119(19):4391-4
references.pmid: 22331188
references.citation: QJM. 2012 Jul;105(7):617-31
references.pmid: 22223674
references.citation: Blood. 2007 Jul 15;110(2):787-8
references.pmid: 17606766
references.citation: Contrib Nephrol. 2007;153:195-210
references.pmid: 17075231
references.citation: Blood. 2011 Jul 28;118(4):865-73
references.pmid: 21562045
references.citation: J Clin Oncol. 2010 Feb 20;28(6):1031-7
references.pmid: 20085941
references.citation: J Natl Compr Canc Netw. 2007 Feb;5(2):179-87
references.pmid: 17335687
references.citation: Blood. 2007 Jan 15;109(2):457-64
references.pmid: 16990593
references.citation: Haematologica. 2009 Mar;94(3):380-6
references.pmid: 19211640
references.citation: Blood. 2012 May 10;119(19):4343-5
references.pmid: 22577156
references.citation: Ann Hematol. 2012 Jan;91(1):89-92
references.pmid: 21533608
references.citation: Arch Intern Med. 1990 Mar;150(3):629-33
references.pmid: 2310282
references.citation: Amyloid. 2012 Jun;19 Suppl 1:78-80
references.pmid: 22506494
references.citation: N Engl J Med. 1997 Sep 25;337(13):898-909
references.pmid: 9302305
references.citation: Haematologica. 2007 Oct;92(10):1302-7
references.pmid: 18024367
references.citation: Blood. 2013 Apr 25;121(17):3420-7
references.pmid: 23479568
references.citation: Annu Rev Med. 2006;57:223-41
references.pmid: 16409147
references.citation: Blood. 2012 Jun 7;119(23):5397-404
references.pmid: 22493299
references.citation: N Engl J Med. 1997 Apr 24;336(17):1202-7
references.pmid: 9110907
references.citation: Proteomics Clin Appl. 2013 Jan;7(1-2):136-43
references.pmid: 23184874
references.citation: Blood. 2006 May 1;107(9):3489-91
references.pmid: 16439680